Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for PTLD Prevention in Solid Organ Transplant Recipients
NCT07614282Phase 1Not yet recruiting
- Start
- Dec 2026
- Primary completion
- Jul 2027
01
Overview
Phase 1, open-label, single-arm trial of rituximab in Post-Transplant Lymphoproliferative Disorder (PTLD) and Epstein-Barr virus infection. Primary endpoint: Clearance of EBV DNAemia at 6 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT07614282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07614282.